Status:

UNKNOWN

Calcitriol in the Treatment of Immunoglobulin A Nephropathy

Lead Sponsor:

Peking University First Hospital

Conditions:

Glomerulonephritis

Autoimmune Diseases

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Immunoglobulin A (IgA) nephropathy is the common primary glomerulonephritis in the world. Much literature suggests that vitamin D and its analogs have profound effects on immune system function and gl...

Eligibility Criteria

Inclusion

  • Aged 18-65 years
  • Biopsy-confirmed IgA nephropathy
  • Proteinuria \> 0.8 g/day in 3 consecutive samples within 12 weeks despite ACE inhibitor or angiotensin receptor blocker treatment for at least 3 months or estimated glomerular filtration rate \< 60 ml/min/1.73m2
  • Corrected serum calcium level \< or = 2.45 mmol/l
  • Willingness to give written consent and comply with the study protocol

Exclusion

  • Pregnancy, lactating or childbearing potential without effective method of birth control
  • Severe gastrointestinal disorders that interfere with their ability to receive or absorb oral medication
  • History of malignancy, including leukemia and lymphoma within the past 2 years
  • Systemic infection requiring therapy at study entry
  • Any other severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension
  • History of drug or alcohol abuse within past 2 years
  • Participation in any previous trial on paricalcitol
  • Patients receiving treatment of vitamin D and/or its analogue for other medical reasons within the past 3 months
  • Patients receiving treatment of corticosteroid
  • On other investigational drugs within last 30 days
  • History of a psychological illness or condition such as to interfere with the patient's ability to understand the requirement of the study
  • History of non-compliance
  • Known history of sensitivity or allergy to paricalcitol or other vitamin D analogs

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2011

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00862693

Start Date

March 1 2009

End Date

March 1 2011

Last Update

February 17 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Renal Division, Peking University First Hospital

Beijing, Beijing Municipality, China, 100034